Akebia Therapeutics Inc (AKBA)

[Laszlo1]

Buy out rumor

[Frankestin]

Bull trap

[Tom turtles]

Nice head fake today.....geez...up 2 cents now pre m

[Bigstud is here]

Look like I bought on the highside. lol

[Porterhouse10]

.33c

[Bigstud is here]

Bought .516 Let c what is does

[willlbone]

Got my lawyers, Dewey, Cheatem & Howe.

[Frankestin]

beautiful soul who eliminated my message because vulgar: So is it okay?
FTS
I'm sorry for all the bulls here!
I fell into the trap of the shorts!!
I didn't want to enter but I saw a lot of passion in shorttwits.com... I have to say that I feel lucky, lately I had lost some motivation in FTS!
Today I am full of energy!
Revenge is needed!
But here they won it must be admitted! Well, there is a place that sizzles... many of you know it!
We are waiting for a nice short squeeze! Get revenge! Maybe it was better that you weren't out of CTIC, don't you think!
FTS

[willlbone]

2 hour trading halt then 70% drop.

[J2003]

Offering? What happened here?

[willlbone]

Snap.

[Frankestin]

Ouch!
at this point luckily to have few!

[Frankestin]

I went in for that!
however I like the halt!
I have an idea this is going to be epic!
too bad to have a few!

[Brunswicknc1]

Don't like the 17% drop this morning, insider info?

[Frankestin]

halted! fingers crossed!

[Frankestin]

what great sons of good women! why wait?
I got a handful now!
Nobody should know!

[Limey42]

I believe the run up has started :)

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
       
    Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover    
    
  
   01/31/2022	11,223,400	9.94	3,731,790	3.01 
   01/14/2022	10,208,646	(10.03)	2,766,551	3.69 
   12/31/2021	11,346,226	(4.28)	4,197,043	2.70 
   12/15/2021	11,853,560	4.15	3,389,521	3.50  
   11/30/2021	11,381,738	10.27	2,606,847	4.37  
   11/15/2021	10,321,801	(11.18)	2,571,872	4.01  
   10/29/2021	11,621,533	1.93	1,631,583	7.12  
   10/15/2021	11,401,612	(10.17)	1,525,420	7.47   
   09/30/2021	12,691,949	1.55	1,888,066	6.72   
   09/15/2021	12,498,541	(6.61)	2,016,986	6.20   
   08/31/2021	13,383,369	2.90	2,331,107	5.74   
   08/13/2021	13,006,081	(6.94)	3,117,676	4.17   
   07/30/2021	13,975,782	(10.97)	6,237,843	2.24   
   07/15/2021	15,697,762	2.89	2,948,475	5.32   
   06/30/2021	15,256,778	(2.24)	4,315,067	3.54   
   06/15/2021	15,606,132	(2.97)	4,133,920	3.78   
   05/28/2021	16,084,404	(11.74)	1,975,283	8.14   
   05/14/2021	18,224,584	(0.29)	3,208,748	5.68   
   04/30/2021	18,277,246	(7.17)	2,688,159	6.80   
   04/15/2021	19,688,699	(7.56)	3,316,031	5.94   
   03/31/2021	21,298,160	(15.24)	4,601,194	4.63   
   03/15/2021	25,126,126	(1.47)	4,884,909	5.14   
   02/26/2021	25,500,922	(3.23)	7,116,615	3.58   
   02/12/2021	26,352,568	(4.01)	8,612,303	3.06   
   01/29/2021	27,453,386	(4.73)	7,193,325	3.82   
   01/15/2021	28,817,129	0.49	5,274,272	5.46    
   12/31/2020	28,675,599	20.84    5,040,993	5.69    
   12/15/2020	23,730,064	0.79	 5,157,773	4.60    
   11/30/2020	23,543,896	(6.18)	 4,207,173	5.60    
   11/13/2020	25,095,299	(6.10)	 5,145,547	4.88    
   10/30/2020	26,725,097	7.62    10,055,146	2.66    
   10/15/2020	24,831,748	12.02	 6,340,540	3.92    
   09/30/2020	22,166,741	141.79	 8,619,035	2.57    
   09/15/2020	9,167,693	12.37   15,663,814	1.00    
   08/31/2020	8,158,475	(10.01)    972,986	8.38    
   08/14/2020	9,065,803	(5.28)	   954,760	9.50    
   07/31/2020	9,571,518	(1.70)	   734,079	13.04    
   07/15/2020	9,737,356	1.00	 1,218,888	7.99    
   06/30/2020	9,641,252	61.40	 1,937,554	4.98    
   06/15/2020	5,973,562	18.54	 1,165,721	5.12    
   05/29/2020	5,039,409	(21.29)	 1,014,751	4.97    
   05/15/2020	6,402,203	(16.02)	 3,532,134	1.81    
   04/30/2020	7,623,059	3.81	   746,700	10.21    
   04/15/2020	7,343,578	8.37	   890,711	8.24    
   03/31/2020	6,776,645	(6.55)	 1,423,097	4.76    
   03/13/2020	7,251,762	(2.38)	 1,737,624	4.17    
   02/28/2020	7,428,762	(5.55)	 1,760,016	4.22    
   02/14/2020	7,865,192	(9.56)	 1,168,402	6.73    
   01/31/2020	8,696,150	(6.94)	 1,279,885	6.79    
   01/15/2020	9,344,280	(5.07)	   896,753	10.42    
        
    
  

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
     
   Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover   
  
  
  12/15/2021	11,853,560	4.15	3,389,521	3.50 
  11/30/2021	11,381,738	10.27	2,606,847	4.37 
  11/15/2021	10,321,801	(11.18)	2,571,872	4.01 
  10/29/2021	11,621,533	1.93	1,631,583	7.12 
  10/15/2021	11,401,612	(10.17)	1,525,420	7.47  
  09/30/2021	12,691,949	1.55	1,888,066	6.72  
  09/15/2021	12,498,541	(6.61)	2,016,986	6.20  
  08/31/2021	13,383,369	2.90	2,331,107	5.74  
  08/13/2021	13,006,081	(6.94)	3,117,676	4.17  
  07/30/2021	13,975,782	(10.97)	6,237,843	2.24  
  07/15/2021	15,697,762	2.89	2,948,475	5.32  
  06/30/2021	15,256,778	(2.24)	4,315,067	3.54  
  06/15/2021	15,606,132	(2.97)	4,133,920	3.78  
  05/28/2021	16,084,404	(11.74)	1,975,283	8.14  
  05/14/2021	18,224,584	(0.29)	3,208,748	5.68  
  04/30/2021	18,277,246	(7.17)	2,688,159	6.80  
  04/15/2021	19,688,699	(7.56)	3,316,031	5.94  
  03/31/2021	21,298,160	(15.24)	4,601,194	4.63  
  03/15/2021	25,126,126	(1.47)	4,884,909	5.14  
  02/26/2021	25,500,922	(3.23)	7,116,615	3.58  
  02/12/2021	26,352,568	(4.01)	8,612,303	3.06  
  01/29/2021	27,453,386	(4.73)	7,193,325	3.82  
  01/15/2021	28,817,129	0.49	5,274,272	5.46   
  12/31/2020	28,675,599	20.84    5,040,993	5.69   
  12/15/2020	23,730,064	0.79	 5,157,773	4.60   
  11/30/2020	23,543,896	(6.18)	 4,207,173	5.60   
  11/13/2020	25,095,299	(6.10)	 5,145,547	4.88   
  10/30/2020	26,725,097	7.62    10,055,146	2.66   
  10/15/2020	24,831,748	12.02	 6,340,540	3.92   
  09/30/2020	22,166,741	141.79	 8,619,035	2.57   
  09/15/2020	9,167,693	12.37   15,663,814	1.00   
  08/31/2020	8,158,475	(10.01)    972,986	8.38   
  08/14/2020	9,065,803	(5.28)	   954,760	9.50   
  07/31/2020	9,571,518	(1.70)	   734,079	13.04   
  07/15/2020	9,737,356	1.00	 1,218,888	7.99   
  06/30/2020	9,641,252	61.40	 1,937,554	4.98   
  06/15/2020	5,973,562	18.54	 1,165,721	5.12   
  05/29/2020	5,039,409	(21.29)	 1,014,751	4.97   
  05/15/2020	6,402,203	(16.02)	 3,532,134	1.81   
  04/30/2020	7,623,059	3.81	   746,700	10.21   
  04/15/2020	7,343,578	8.37	   890,711	8.24   
  03/31/2020	6,776,645	(6.55)	 1,423,097	4.76   
  03/13/2020	7,251,762	(2.38)	 1,737,624	4.17   
  02/28/2020	7,428,762	(5.55)	 1,760,016	4.22   
  02/14/2020	7,865,192	(9.56)	 1,168,402	6.73   
  01/31/2020	8,696,150	(6.94)	 1,279,885	6.79   
  01/15/2020	9,344,280	(5.07)	   896,753	10.42   
      
  
 

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

   
  Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover  
  
 10/15/2021	11,401,612	(10.17)	1,525,420	7.47 
 09/30/2021	12,691,949	1.55	1,888,066	6.72 
 09/15/2021	12,498,541	(6.61)	2,016,986	6.20 
 08/31/2021	13,383,369	2.90	2,331,107	5.74 
 08/13/2021	13,006,081	(6.94)	3,117,676	4.17 
 07/30/2021	13,975,782	(10.97)	6,237,843	2.24 
 07/15/2021	15,697,762	2.89	2,948,475	5.32 
 06/30/2021	15,256,778	(2.24)	4,315,067	3.54 
 06/15/2021	15,606,132	(2.97)	4,133,920	3.78 
 05/28/2021	16,084,404	(11.74)	1,975,283	8.14 
 05/14/2021	18,224,584	(0.29)	3,208,748	5.68 
 04/30/2021	18,277,246	(7.17)	2,688,159	6.80 
 04/15/2021	19,688,699	(7.56)	3,316,031	5.94 
 03/31/2021	21,298,160	(15.24)	4,601,194	4.63 
 03/15/2021	25,126,126	(1.47)	4,884,909	5.14 
 02/26/2021	25,500,922	(3.23)	7,116,615	3.58 
 02/12/2021	26,352,568	(4.01)	8,612,303	3.06 
 01/29/2021	27,453,386	(4.73)	7,193,325	3.82 
 01/15/2021	28,817,129	0.49	5,274,272	5.46  
 12/31/2020	28,675,599	20.84    5,040,993	5.69  
 12/15/2020	23,730,064	0.79	 5,157,773	4.60  
 11/30/2020	23,543,896	(6.18)	 4,207,173	5.60  
 11/13/2020	25,095,299	(6.10)	 5,145,547	4.88  
 10/30/2020	26,725,097	7.62    10,055,146	2.66  
 10/15/2020	24,831,748	12.02	 6,340,540	3.92  
 09/30/2020	22,166,741	141.79	 8,619,035	2.57  
 09/15/2020	9,167,693	12.37   15,663,814	1.00  
 08/31/2020	8,158,475	(10.01)    972,986	8.38  
 08/14/2020	9,065,803	(5.28)	   954,760	9.50  
 07/31/2020	9,571,518	(1.70)	   734,079	13.04  
 07/15/2020	9,737,356	1.00	 1,218,888	7.99  
 06/30/2020	9,641,252	61.40	 1,937,554	4.98  
 06/15/2020	5,973,562	18.54	 1,165,721	5.12  
 05/29/2020	5,039,409	(21.29)	 1,014,751	4.97  
 05/15/2020	6,402,203	(16.02)	 3,532,134	1.81  
 04/30/2020	7,623,059	3.81	   746,700	10.21  
 04/15/2020	7,343,578	8.37	   890,711	8.24  
 03/31/2020	6,776,645	(6.55)	 1,423,097	4.76  
 03/13/2020	7,251,762	(2.38)	 1,737,624	4.17  
 02/28/2020	7,428,762	(5.55)	 1,760,016	4.22  
 02/14/2020	7,865,192	(9.56)	 1,168,402	6.73  
 01/31/2020	8,696,150	(6.94)	 1,279,885	6.79  
 01/15/2020	9,344,280	(5.07)	   896,753	10.42  
    

[XenaLives]

Institutional interest creeping up -

2019:

Institutional Shares (Long) 89,761,616 - 51.43% (ex 13D/G) - change of shares - change of % MRQ

https://fintel.io/so/us/akba?d=2019-09-30

Current:

Institutional Shares (Long) 127,886,041 - 73.27% (ex 13D/G)
https://fintel.io/so/us/akba?d=2019-09-30

[historyperson]

I've accumulated a few hundred shares since finding out about Akebia earlier this year. This could be my next big investment after AUPH is bought out or I sell at $40.

But one question, should I be worried about Auryxia revenue at all? "Net Product Revenue for Auryxia® (ferric citrate) Increases to $33.0 Million, Up 7.4% from Q2'FY20"

That doesn't seem like great growth for a relatively new drug a year after a terrible (covid) quarter...

Or is it all about the future of Vadadustat?

Thank you. Rooting for AKBA and hoping to continue to add below $4.

[XenaLives]

Finally, a bottom???

[XenaLives]

9/3/20 gap down on this news:

https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-announces-top-line-results-its-pro2tect

[XenaLives]

What's the scoop on this?

Item 1.01 Entry into a Material Definitive Agreement.
On April 17, 2019 (the “Effective Date”), Akebia Therapeutics, Inc. (the “Company”) and Panion & BF Biotech, Inc. (“Panion”) entered into a second
amended and restated license agreement (the “Amended License Agreement”). The Amended License Agreement amends and restates in full the prior
amended and restated license agreement effective March 17, 2008, as amended, between Panion and Keryx Biopharmaceuticals, Inc. (“Keryx”) pursuant to
which Keryx in-licensed exclusive worldwide rights, excluding certain Asian-Pacific countries, for the development, marketing and commercialization of
ferric citrate (the “Original Agreement”). As previously disclosed, the Company and Keryx completed a merger on December 12, 2018, and as a result,
Keryx is now the Company’s wholly owned subsidiary. The Amended License Agreement reflects certain revisions consistent with the terms of the letter
agreement among the Company, Panion and Keryx entered into on October 24, 2018 that was previously disclosed (the “Letter Agreement”).
Like the Original Agreement, the Amended License Agreement provides the Company with an exclusive license under Panion-ownedknow-how and
patents covering the rights to sublicense, develop, make, use, sell, offer for sale, import and export ferric citrate worldwide, excluding certain Asian-Pacific
countries. Consistent with the terms set forth in the Letter Agreement, the Amended License Agreement also provides Panion with an exclusive license
under Keryx-owned patents covering the rights to sublicense (with the Company’s written consent), develop, make, use, sell, offer for sale, import and
export ferric citrate in certain countries in the Asia-Pacific region (the “Licensor Territory”). Consistent with the Original Agreement, under the Amended
License Agreement, Panion is eligible to receive from the Company or any sublicensee royalty payments based on a mid-single digit percentage of sales of
ferric citrate in the Company’s licensed territories. Consistent with the terms set forth in the Letter Agreement, under the Amended License Agreement, the
Company is eligible to receive from Panion or any sublicensee royalty payments based on a mid-single digit percentage of net sales of ferric citrate in
Panion’s licensed territories.
Pursuant to the terms of the Amended License Agreement and consistent with the terms set forth in the Letter Agreement, a joint steering committee (“JSC”)
consisting of Panion and Company representatives will be formed to oversee the development and commercialization of Fexeric in Europe. As set forth in
the Letter Agreement, the JSC will work together to reach consensus on a commercialization plan and, in the event a commercialization plan is not agreed
upon within a certain period after the Effective Date, the Company, in its discretion, may launch ferric citrate in certain European countries within a certain
period after the Effective Date, pay an annual license maintenance fee to Panion, or expand the Licensor Territory to include the European Union on terms
to be negotiated by the parties. The Amended License Agreement further provides that each of the Company and Panion has the right, but not the obligation,
to conduct litigation against any infringer of certain patent rights under the agreement in certain territories.
The Amended License Agreement terminates upon the expiration of each of the Company’s and Panion’s obligations to pay royalties thereunder. In
addition, the Company may terminate the Amended License Agreement (i) in its entirety or (ii) with respect to one or more countries in the Company’s
licensed territory, in either case upon 90 days’ notice. The Company and Panion also each have the right to terminate the Amended License Agreement upon
the occurrence of a material breach of the Amended License Agreement by the other party, subject to certain cure provisions, or certain insolvency events.
The Amended License Agreement also provides that, on a country-by-country basis, until the second anniversary of the expiration of the obligation of the
Company or Panion, as applicable, to pay royalties in a country in which such party has ferric citrate for sale on the date of such expiration, neither the other
party nor its affiliates will, directly or indirectly, sell, distribute or otherwise commercialize or supply or cause to supply ferric citrate to a third party for sale
or distribution in such country.
The Amended License Agreement includes customary terms relating to, among others, indemnification, confidentiality, remedies, and representations and
warranties.

https://ir.akebia.com/static-files/57917a95-fccc-431a-ae03-bd7c773c3a3f

[XenaLives]

New 13G

File Date	Form	Security		Prev 
 Shares	Current  
 Shares	Change 
 (Percent)	Ownership 
 (Percent)	Change 
 (Percent) 
  
 2021-07-12	13G/A	STATE STREET CORP			14,006,637		8.75	 
 2021-02-12	13G/A	Nantahala Capital Management, LLC 	7,040,487		4.90	 
 2021-02-10	13G	VANGUARD GROUP INC			8,434,759		5.84	 
 2021-02-03	13G/A	WELLINGTON MANAGEMENT GROUP LLP 	12,590,463		8.71	 
 2021-01-29	13G/A	BlackRock Inc.			      11,397,548		7.90	

https://fintel.io/so/us/akba

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
    
   Settlement Date	Short Interest	Percent Change	Average Daily Share Volume	Days to Cover  
   
     06/15/2021	15,606,132	(2.97)	  4,133,920	3.78 
     05/28/2021	16,084,404	(11.74)	  1,975,283	8.14 
     05/14/2021	18,224,584	(0.29)	  3,208,748	5.68 
     04/30/2021	18,277,246	(7.17)	  2,688,159	6.80  
     04/15/2021	19,688,699	(7.56)	  3,316,031	5.94  
     03/31/2021	21,298,160	(15.24)	  4,601,194	4.63  
     03/15/2021	25,126,126	(1.47)	  4,884,909	5.14  
     02/26/2021	25,500,922	(3.23)	  7,116,615	3.58  
     02/12/2021	26,352,568	(4.01)	  8,612,303	3.06     
     01/29/2021	27,453,386	(4.73)    7,193,325	3.82    
     01/15/2021	28,817,129	 0.49	  5,274,272	5.46    
     12/31/2020	28,675,599	20.84     5,040,993	5.69     
     12/15/2020	23,730,064	 0.79	  5,157,773	4.60     
     11/30/2020	23,543,896	(6.18)	  4,207,173	5.60     
     11/13/2020	25,095,299	(6.10)	  5,145,547	4.88     
     10/30/2020	26,725,097	 7.62    10,055,146	2.66     
     10/15/2020	24,831,748	12.02	  6,340,540	3.92     
     09/30/2020	22,166,741     141.79	  8,619,035	2.57     
     09/15/2020	9,167,693	12.37    15,663,814	1.00     
     08/31/2020	8,158,475      (10.01)      972,986	8.38     
     08/14/2020	9,065,803	(5.28)	    954,760	9.50     
     07/31/2020	9,571,518	(1.70)	    734,079	13.04     
     07/15/2020	9,737,356	 1.00	  1,218,888	7.99     
     06/30/2020	9,641,252	61.40	  1,937,554	4.98     
     06/15/2020	5,973,562	18.54	  1,165,721	5.12     
     05/29/2020	5,039,409	(21.29)	  1,014,751	4.97     
     05/15/2020	6,402,203	(16.02)	  3,532,134	1.81     
     04/30/2020	7,623,059	3.81	    746,700	10.21     
     04/15/2020	7,343,578	8.37	    890,711	8.24     
     03/31/2020	6,776,645	(6.55)	  1,423,097	4.76     
     03/13/2020	7,251,762	(2.38)	  1,737,624	4.17     
     02/28/2020	7,428,762	(5.55)	  1,760,016	4.22     
     02/14/2020	7,865,192	(9.56)	  1,168,402	6.73     
     01/31/2020	8,696,150	(6.94)	  1,279,885	6.79     
     01/15/2020	9,344,280	(5.07)	    896,753	10.42     
     
  
 

[XenaLives]

More Yahoo eavesdropping...

$AKBA conversation
Back in September 2019, AKBA was at a similar price as it is today, and was mired in low retail confidence. Then one day, Butler and company bought about 150K shares of stock. This action gave a jolt to investor confidence and the stock rose ~400% in the next eight months. The present fundamentals appear to be sound. The sad stock price situation today could changed by another jolt of ~150K shares of insider buying! Come on management, it's about time you showed some consideration for your stockholders.

ReplyReplies (1)71
Seth
Seth3 months ago
$FGEN conversation
I am a long time AKBA holder/sufferer - my advice to you is very simple, don't try to catch the " falling knife". AKBA suffered similar disappointment last September, although AKAB's was due to an honest representation of the MACE data whereas FGEN appears to have introduced some ad-hoc data manipulation. AKBA's stock fell about 75% in a single day. Investor confidence in AKBA was severely damaged, and remains so even today, some seven months later. Low investor confidence means very low buying pressure, resulting in an environment where the high volume, small trade, computer generated shorts rule the day. I see a similar path for FGEN - be aware and be careful!

https://ca.finance.yahoo.com/quote/AKBA/community/

[XenaLives]

Akebia wins $40M Department of Veterans Affairs contract

Akebia Therapeutics (AKBA -3.8%) has been awarded a federal supply contract from the Department of Veterans Affairs. The contract awarded today is valued at $40.2M and runs for five years from July 01, 2021.
The small-cap company, Akebia focused on patients with chronic kidney disease (CKD) saw its net product revenue rise ~4% YoY to $30.4M in Q1 2021.
The company’s topline relies on Auryxia which is approved in the U.S. for the control of serum phosphorus levels in dialysis-dependent CKD adult patients and also for the treatment of iron deficiency anemia in CKD adult patients who are not dependent on dialysis.
The company with its partner, Otsuka Pharmaceutical has sought the marketing approval for vadadustat for the treatment of anemia in adults with CKD irrespective of their dialysis status.

https://newsfilter.io/articles/akebia-wins-40m-department-of-veterans-affairs-contract-0668f600ff9f7c0144a99d669b113876

[XenaLives]

Vadadustat: First Approval
Anthony Markham 1
Affiliations expand
PMID: 32852744 DOI: 10.1007/s40265-020-01383-z
Abstract
Vadadustat (VAFSEO®) is a prolyl hydroxylase inhibitor being developed by Akebia Therapeutics, Inc. (Akebia) for the treatment of anaemia associated with chronic kidney disease (CKD). Akebia is collaborating with Mitsubishi Tanabe Pharma Corporation on the development and commercialization of vadadustat in Japan and with Otsuka Pharmaceutical Co. Ltd on the development and commercialization of vadadustat in the USA, the EU and certain other territories. The drug is approved in Japan for use in adult patients with anaemia associated with CKD and regulatory submissions are planned in the USA and the EU. This article summarizes the milestones in the development of vadadustat leading to this first approval.

https://pubmed.ncbi.nlm.nih.gov/32852744/

[XenaLives]

Brought back here because of the chart:


SA info lifted from Yahoo convo:

Akebia wins $40M Department of Veterans Affairs contract

Jun. 15, 2021 3:06 PM ETAkebia Therapeutics, Inc. (AKBA)By: Dulan Lokuwithana, SA News Editor
The specialist are doing continuous renal replacement therapy equipment and injection pump.
saengsuriya13/iStock via Getty Images
Akebia Therapeutics (AKBA -3.8%) has been awarded a federal supply contract from the Department of Veterans Affairs. The contract awarded today is valued at $40.2M and runs for five years from July 01, 2021.
The small-cap company, Akebia focused on patients with chronic kidney disease (CKD) saw its net product revenue rise ~4% YoY to $30.4M in Q1 2021.
The company’s topline relies on Auryxia which is approved in the U.S. for the control of serum phosphorus levels in dialysis-dependent CKD adult patients and also for the treatment of iron deficiency anemia in CKD adult patients who are not dependent on dialysis.
The company with its partner, Otsuka Pharmaceutical has sought the marketing approval for vadadustat for the treatment of anemia in adults with CKD irrespective of their dialysis status.

[MADDSTACKER]

40 m contract . ?

[XenaLives]

High institutional ownership..

https://fintel.io/so/us/akba

[jonny_red]

AKBA is the trade for me today! #TTBlackbox

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

  
  Settlement Date	Short Interest	Percent Change	Average Daily Share Volume	Days to Cover  
  
    04/30/2021	18,277,246	(7.17)	  2,688,159	6.80 
    04/15/2021	19,688,699	(7.56)	  3,316,031	5.94 
    03/31/2021	21,298,160	(15.24)	  4,601,194	4.63 
    03/15/2021	25,126,126	(1.47)	  4,884,909	5.14 
    02/26/2021	25,500,922	(3.23)	  7,116,615	3.58 
    02/12/2021	26,352,568	(4.01)	  8,612,303	3.06    
    01/29/2021	27,453,386	(4.73)    7,193,325	3.82   
    01/15/2021	28,817,129	 0.49	  5,274,272	5.46   
    12/31/2020	28,675,599	20.84     5,040,993	5.69    
    12/15/2020	23,730,064	 0.79	  5,157,773	4.60    
    11/30/2020	23,543,896	(6.18)	  4,207,173	5.60    
    11/13/2020	25,095,299	(6.10)	  5,145,547	4.88    
    10/30/2020	26,725,097	 7.62    10,055,146	2.66    
    10/15/2020	24,831,748	12.02	  6,340,540	3.92    
    09/30/2020	22,166,741     141.79	  8,619,035	2.57    
    09/15/2020	9,167,693	12.37    15,663,814	1.00    
    08/31/2020	8,158,475      (10.01)      972,986	8.38    
    08/14/2020	9,065,803	(5.28)	    954,760	9.50    
    07/31/2020	9,571,518	(1.70)	    734,079	13.04    
    07/15/2020	9,737,356	 1.00	  1,218,888	7.99    
    06/30/2020	9,641,252	61.40	  1,937,554	4.98    
    06/15/2020	5,973,562	18.54	  1,165,721	5.12    
    05/29/2020	5,039,409	(21.29)	  1,014,751	4.97    
    05/15/2020	6,402,203	(16.02)	  3,532,134	1.81    
    04/30/2020	7,623,059	3.81	    746,700	10.21    
    04/15/2020	7,343,578	8.37	    890,711	8.24    
    03/31/2020	6,776,645	(6.55)	  1,423,097	4.76    
    03/13/2020	7,251,762	(2.38)	  1,737,624	4.17    
    02/28/2020	7,428,762	(5.55)	  1,760,016	4.22    
    02/14/2020	7,865,192	(9.56)	  1,168,402	6.73    
    01/31/2020	8,696,150	(6.94)	  1,279,885	6.79    
    01/15/2020	9,344,280	(5.07)	    896,753	10.42    
   

[XenaLives]

Do you mean 100 share transactions? That's algo trading.

[Cowboydog]

Whats with all the $100 transactions? wtf.

[Cowboydog]

Yea I see where the short interest is around 20%. Somebody just upgraded them! About time imo.

[hrhmmuld]

Squeeze potential

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
 Settlement Date	Short Interest	Percent Change	Average Daily Share Volume	Days to Cover 
  
   02/12/2021	26,352,568	(4.01)	  8,612,303	3.06   
   01/29/2021	27,453,386	(4.73)    7,193,325	3.82  
   01/15/2021	28,817,129	 0.49	  5,274,272	5.46  
   12/31/2020	28,675,599	20.84     5,040,993	5.69   
   12/15/2020	23,730,064	 0.79	  5,157,773	4.60   
   11/30/2020	23,543,896	(6.18)	  4,207,173	5.60   
   11/13/2020	25,095,299	(6.10)	  5,145,547	4.88   
   10/30/2020	26,725,097	 7.62    10,055,146	2.66   
   10/15/2020	24,831,748	12.02	  6,340,540	3.92   
   09/30/2020	22,166,741     141.79	  8,619,035	2.57   
   09/15/2020	9,167,693	12.37    15,663,814	1.00   
   08/31/2020	8,158,475      (10.01)      972,986	8.38   
   08/14/2020	9,065,803	(5.28)	    954,760	9.50   
   07/31/2020	9,571,518	(1.70)	    734,079	13.04   
   07/15/2020	9,737,356	 1.00	  1,218,888	7.99   
   06/30/2020	9,641,252	61.40	  1,937,554	4.98   
   06/15/2020	5,973,562	18.54	  1,165,721	5.12   
   05/29/2020	5,039,409	(21.29)	  1,014,751	4.97   
   05/15/2020	6,402,203	(16.02)	  3,532,134	1.81   
   04/30/2020	7,623,059	3.81	    746,700	10.21   
   04/15/2020	7,343,578	8.37	    890,711	8.24   
   03/31/2020	6,776,645	(6.55)	  1,423,097	4.76   
   03/13/2020	7,251,762	(2.38)	  1,737,624	4.17   
   02/28/2020	7,428,762	(5.55)	  1,760,016	4.22   
   02/14/2020	7,865,192	(9.56)	  1,168,402	6.73   
   01/31/2020	8,696,150	(6.94)	  1,279,885	6.79   
   01/15/2020	9,344,280	(5.07)	    896,753	10.42   
           
  
 

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

  
    
  Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover  
    
  01/29/2021	27,453,386	(4.73)    7,193,325	3.82 
  01/15/2021	28,817,129	 0.49	  5,274,272	5.46 
  12/31/2020	28,675,599	20.84     5,040,993	5.69  
  12/15/2020	23,730,064	 0.79	  5,157,773	4.60  
  11/30/2020	23,543,896	(6.18)	  4,207,173	5.60  
  11/13/2020	25,095,299	(6.10)	  5,145,547	4.88  
  10/30/2020	26,725,097	 7.62    10,055,146	2.66  
  10/15/2020	24,831,748	12.02	  6,340,540	3.92  
  09/30/2020	22,166,741     141.79	  8,619,035	2.57  
  09/15/2020	9,167,693	12.37    15,663,814	1.00  
  08/31/2020	8,158,475      (10.01)      972,986	8.38  
  08/14/2020	9,065,803	(5.28)	    954,760	9.50  
  07/31/2020	9,571,518	(1.70)	    734,079	13.04  
  07/15/2020	9,737,356	 1.00	  1,218,888	7.99  
  06/30/2020	9,641,252	61.40	  1,937,554	4.98  
  06/15/2020	5,973,562	18.54	  1,165,721	5.12  
  05/29/2020	5,039,409	(21.29)	  1,014,751	4.97  
  05/15/2020	6,402,203	(16.02)	  3,532,134	1.81  
  04/30/2020	7,623,059	3.81	    746,700	10.21  
  04/15/2020	7,343,578	8.37	    890,711	8.24  
  03/31/2020	6,776,645	(6.55)	  1,423,097	4.76  
  03/13/2020	7,251,762	(2.38)	  1,737,624	4.17  
  02/28/2020	7,428,762	(5.55)	  1,760,016	4.22  
  02/14/2020	7,865,192	(9.56)	  1,168,402	6.73  
  01/31/2020	8,696,150	(6.94)	  1,279,885	6.79  
  01/15/2020	9,344,280	(5.07)	    896,753	10.42  
     
   

[XenaLives]

Anyone here following this long term?

I did basic DD, just posted and it looked like a good chart set up.

Haven't decided about long term weight.

[XenaLives]

Apparently so ....

[CASHOUTKING]

Some interest is forming again in this stock

[XenaLives]

Bought some more today..

... the chart made me do it.

[jimmy667]

Very good DD...as usual.
Looks good to me.

[XenaLives]

Easily referenced presentations..

Haven't had time to go over these yet but they look comprehensive:

https://ir.akebia.com/data-presentations

[XenaLives]

Historic Short Interest:


You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch

 
  
 Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover 
  
 12/31/2020	28,675,599	20.84    5,040,993	5.69 
 12/15/2020	23,730,064	0.79	 5,157,773	4.60 
 11/30/2020	23,543,896	(6.18)	 4,207,173	5.60 
 11/13/2020	25,095,299	(6.10)	 5,145,547	4.88 
 10/30/2020	26,725,097	7.62    10,055,146	2.66 
 10/15/2020	24,831,748	12.02	 6,340,540	3.92 
 09/30/2020	22,166,741	141.79	 8,619,035	2.57 
 09/15/2020	9,167,693	12.37   15,663,814	1.00 
 08/31/2020	8,158,475	(10.01)    972,986	8.38 
 08/14/2020	9,065,803	(5.28)	   954,760	9.50 
 07/31/2020	9,571,518	(1.70)	   734,079	13.04 
 07/15/2020	9,737,356	1.00	 1,218,888	7.99 
 06/30/2020	9,641,252	61.40	 1,937,554	4.98 
 06/15/2020	5,973,562	18.54	 1,165,721	5.12 
 05/29/2020	5,039,409	(21.29)	 1,014,751	4.97 
 05/15/2020	6,402,203	(16.02)	 3,532,134	1.81 
 04/30/2020	7,623,059	3.81	   746,700	10.21 
 04/15/2020	7,343,578	8.37	   890,711	8.24 
 03/31/2020	6,776,645	(6.55)	 1,423,097	4.76 
 03/13/2020	7,251,762	(2.38)	 1,737,624	4.17 
 02/28/2020	7,428,762	(5.55)	 1,760,016	4.22 
 02/14/2020	7,865,192	(9.56)	 1,168,402	6.73 
 01/31/2020	8,696,150	(6.94)	 1,279,885	6.79 
 01/15/2020	9,344,280	(5.07)	   896,753	10.42 
   
  
  
 

[XenaLives]

Institutional ownership:

Industry Pharmaceutical Preparations
Institutional Owners 402
Institutional Shares 147,264,272 - 101.89% (ex 13D/G)
Institutional Value $ 450,578 USD ($1000)

Recent 13 G/D

 
 File Date	Form	Security		Prev 
 Shares	Current 
 Shares	Change 
 (Percent)	Ownership 
 (Percent)	Change 
 (Percent) 
 2020-11-10	13G	WELLINGTON MANAGEMENT GROUP LLP			17,698,113		12.35	 
 2020-10-13	13G/A	STATE STREET CORP			15,340,471		10.70	 
 2020-10-09	13G/A	BAUPOST GROUP LLC/MA			0		0.00	 
 2020-02-13	13G	Nantahala Capital Management, LLC			6,737,120		5.70	 
 2020-02-05	13G/A	BlackRock Inc.			10,261,147		8.60	 
 2019-02-14	13G/A	ABRAMS CAPITAL MANAGEMENT, L.P.						 
 2019-01-11	13D/A	Satter Muneer A			3,067,043		2.60	 
 2019-01-07	13G/A	Novo Holdings A/S			3,100,000		

Recent 13F

 
 File Date	Form	Investor		Opt	Avg Share Price	Shares	Shares Changed 
 (%)	Value 
 ($1000)	Value Changed 
 (%)	Cost Basis 
 (x1000)	Profit 
 (x1000)	Return 
 (%) 
 2020-11-10	13F	State Street Corp			8.04	15,340,471	206.07	38,505	-43.43			 
 2020-11-27	NP	XBI - SPDR(R) S&P(R) Biotech ETF				12,615,105		31,664				 
 2020-11-06	13F	BlackRock Inc.			8.05	11,744,162	3.35	29,480	-80.90			 
 2020-11-16	13F	Wellington Management Group Llp			8.04	7,924,972	8.94	19,892	-79.86			 
 2020-11-16	13F	Avidity Partners Management LP				7,324,000		18,383				 
 2020-11-16	13F	Vanguard Group Inc			8.04	6,565,065	-10.32	16,478	-83.43			 
 2020-11-16	13F	Nantahala Capital Management, LLC			8.04	5,746,623	-5.81	14,424	-82.59			 
 2020-11-13	13F	Abrams Capital Management, L.p.			8.04	5,656,462	0.00	14,198	-81.52			 
 2020-11-16	13F	Woodline Partners LP			8.05	5,458,936	747.36	13,702	56.61			 
 2020-11-27	NP	VTSMX - Vanguard Total Stock Market Index Fund Investor Shares				3,310,423		8,309				 
 2020-11-25	NP	IWM - iShares Russell 2000 ETF				2,912,340		7,310				 
 2020-12-29	NP	VEXPX - VANGUARD EXPLORER FUND Investor Shares				2,706,816		6,009				 
  
 

https://fintel.io/so/us/akba

[XenaLives]

Product on the market:

INDICATIONS
AURYXIA® (ferric citrate) is indicated for:

The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis
IMPORTANT SAFETY INFORMATION
CONTRAINDICATION

AURYXIA® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis

https://www.auryxia.com/akebiacares/